Physician profile
Eric A Awad
NPI 1578557500
$121,068.67
in general payments reported to CMS, 2019-2025
82 companies · $35K in 2025
The $35K reported for 2025 was more than what 95% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27K · 2020: $8,276 · 2021: $8,648 · 2022: $3,255 · 2023: $3,588 · 2024: $36K · 2025: $35K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $36K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $13K · Food and Beverage: $12K · Consulting Fee: $8,073 · Travel and Lodging: $5,292 · Education: $99.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $35,500.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $12,577.50 |
| Food and Beverage | $12,341.15 |
| Consulting Fee | $8,072.50 |
| Travel and Lodging | $5,292.39 |
| Education | $99.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $66,074.01 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Eisai INC. | $24,792.57 | 2019-2025 | |
| Genentech USA, INC. | $4,877.68 | 2019-2025 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Biogen, INC. | $3,714.37 | 2019-2025 | Tysabri, Vumerity, Leqembi |
| Abbvie INC. | $2,810.64 | 2019-2025 | Duopa, Qulipta, Ubrelvy |
| Novartis Pharmaceuticals Corporation | $1,684.69 | 2019-2025 | |
| Supernus Pharmaceuticals, INC. | $1,531.85 | 2019-2025 | Qelbree |
| Mdd US Operations, LLC | $1,101.82 | 2019-2025 | Gocovri, Qelbree, Gocovri |
| Pfizer INC. | $992.44 | 2021-2025 | |
| Emd Serono, INC. | $759.09 | 2019-2025 | Mavenclad |
| Amgen INC. | $736.27 | 2019-2025 | Uplizna |
| Ucb, INC. | $734.56 | 2019-2025 | Rystiggo, Zilbrysq |
| Genzyme Corporation | $655.89 | 2019-2025 | |
| Lundbeck LLC | $484.78 | 2020-2025 | Vyepti, Rexulti |
| Teva Pharmaceuticals USA, INC. | $469.95 | 2019-2025 | Austedo Xr, Ajovy, Austedo Xr |
Show all 81 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Awad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.